5023-94-9

Usage

Uses

Used in Organic Synthesis:
3-NITROBENZAMIDOXIME is used as a reagent in organic synthesis for its capacity to participate in various chemical reactions, facilitating the creation of a range of organic compounds.
Used in Research and Industrial Applications:
In research and industrial settings, 3-NITROBENZAMIDOXIME is employed for its metal-chelating properties, which are valuable in numerous applications, including the development of new materials and processes.
Used as a Starting Material for Pharmaceutical Synthesis:
3-NITROBENZAMIDOXIME is utilized as a starting material in the synthesis of pharmaceuticals, owing to its ability to be transformed into other compounds with potential medicinal properties.
Used in Coordination Chemistry:
3-NITROBENZAMIDOXIME is applied in the field of coordination chemistry, where its interaction with metal ions is exploited to study and develop new coordination complexes.
Used in the Development of Metal-Based Drugs:
3-NITROBENZAMIDOXIME holds promise in the development of metal-based drugs, capitalizing on its chelating capabilities to enhance the therapeutic potential of metal ions in medicinal applications.

InChI:InChI=1/C7H7N3O3/c8-7(9-11)5-2-1-3-6(4-5)10(12)13/h1-4,11H,(H2,8,9)

Upstream product

• 619-24-9 3-nitrobenzonitrile 
• 7007-35-4 m-nitrobenzonitrile oxide 
• 503027-47-2 N,N'-bis(trimethylsilyl)sulfurdiimide 
• 7803-49-8 hydroxylamine 
• 3459-99-2 3-nitrobenzamidine 
• 64-17-5 ethanol 
• 100-47-0 benzonitrile 
• 3431-62-7 3-nitrobenzaldoxime 
• 67-56-1 methanol 
• 33512-94-6 m-nitrobenzhydroxamoyl chloride 
• 585-79-5 m-nitrobromobenzene 
• 172469-58-8 4-(3-Nitro-phenyl)-2λ⁴-[1,2,3,5]oxathiadiazol-2-ylamine 

Downstream Products

• 81467-53-0 C₁₁H₁₁N₃O₅ 
• 24794-10-3 1-[3-(3-nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-propan-2-one 
• 20844-48-8 3-(3-nitrophenyl)-5-phenyl-1,2,4-oxadiazole 
• 74229-71-3 3,5-bis(3-nitrophenyl)-1,2,4-oxadiazole 
• 73185-75-8 3-(3-nitro-phenyl)-[1,2,4]oxadiazole-5-carboxylic acid ethyl ester 
• 10185-66-7 5-butyl-3-(3-nitro-phenyl)-[1,2,4]oxadiazole 
• 10364-69-9 5-ethyl-3-(3-nitro-phenyl)-[1,2,4]oxadiazole 
• 33512-94-6 m-nitrobenzhydroxamoyl chloride 
• 90049-83-5 3-(3-nitro-phenyl)-[1,2,4]oxadiazole 
• 25283-98-1 5-methyl-3-(3-nitro-phenyl)-[1,2,4]oxadiazole 

Relevant academic research and scientific papers

Synthesis, in silico, and in vitro evaluation of anti-leishmanial activity of oxadiazoles and indolizine containing compounds flagged against anti-targets

Due to the lack of approved vaccines against human leishmaniasis and the limitations of the current chemotherapy inducing side effects and drug resistance, development of new, effective chemotherapeutic agents is essential. This study describes the synthesis of a series of novel oxadiazoles and indolizine-containing compounds. The compounds were screened in silico using an EIIP/AQVN filter followed by ligand-based virtual screening and molecular docking to parasite arginase. Top hits were further screened versus human arginase and finally against an anti-target battery to tag their possible interactions with proteins essential for the metabolism and clearance of many substances. Eight candidate compounds were selected for further experimental testing. The results show measurable in vitro anti-leishmanial activity for three compounds. One compound with an IC50 value of 2.18 μM on Leishmania donovani intramacrophage amastigotes is clearly better positioned than the others as an interesting molecular template for further development of new anti-leishmanial agents.

Syntheses and biological activity of platinum(II) and palladium(II) complexes with phenyl-oxadiazole-ethylenediamine ligands

This work describes the synthesis, characterization, cytotoxicity and antibacterial activity of three ligands derived from phenyl-oxadiazole-ethylenediamine and their platinum(II) and palladium(II) complexes. These compounds were characterized by elemental analysis, and Raman, IR, and NMR spectroscopies. We have prepared complexes with different substituents on the aromatic ring to provide influence in the antibacterial activity and cytotoxicity. The antibacterial activity was evaluated against Gram-positive bacteria Staphylococcus aureus (ATCC 25213), Staphylococcus epidermidis (ATCC 12228) and Gram-negative bacteria Escherichia coli (ATCC 11229) and Pseudomonas aeruginosa (ATCC 27853). The cytotoxicity was evaluated in two different tumor cell lines: mouse metastatic mammary adenocarcinoma (4T1), and murine colon cancer cells (CT26WT), and a non-tumor cell Baby Hamster Kidney (BHK-21). Based on the results obtained for the antibacterial and the cytotoxic activity it is possible to conclude that the presence of metal and groups NO2 and CF3 contributed to antibacterial activity with low cytotoxicity.

Synthesis and Evaluation of Antibacterial Activity of 1,2,4-Oxadiazole-Containing Biphenylcarboxylic Acids

Abstract: A one-pot method for the synthesis of biphenylcarboxylic acids containing 1,2,4-oxadiazole ring in the NaOH–DMSO system was developed. The results of in vitro experiments showed that the synthesized compounds exhibit antibacterial activity against susceptible strains of E. coli and S. aureus.

Synthesis and Properties of Energetic 1,2,4-Oxadiazoles

The synthesis and characterization of a series of 3,5-di-aryl-1,2,4-oxadiazoles are reported and the effects of nitro groups in the aromatic rings on the experimental heats of decomposition (ΔHd) and heats of combustion (ΔHc) are evaluated. Heats of formation (ΔHf) and densities (ρ) were calculated and correlations between ΔHd and ΔHf were assessed for these compounds. Experimental determination of ρ (by gas pycnometry) on a selection of the compounds led to the calculation of detonation velocity (VD), detonation pressure (PD) and specific impulse (ISP) parameters by the Explo 5 program. An X-ray analysis of compound (4i) confirmed the structure and showed a crystal density (at 120 K) close to that determined by gas pycnometry.

Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents

Abstract In our study, three series of hydroxamate, 2-aminobenzamide, and trifluoromethyl ketone analogues have been designed and synthesized. The synthesized compounds were investigated for their in vitro antiproliferative activities using the MTT-based assay against three human cancer cell lines including A549, NCI-H661, and U937. Most analogues exhibited higher antiproliferative activities against human acute myeloid leukemia cell U937 than the other two human lung cancer cell lines. Furthermore, the compounds were examined against HDAC1, 2, and 8 isoforms. Docking study of compounds 6h, 9b, and 10a suggested that they might bind tightly to the binding pocket of HDAC2 and/or HDAC8. The results suggest that these compounds might have potential as lead compounds for the development of anti-tumor drugs with HDACs inhibitory activities.

One-pot synthesis of amidoxime via Pd-catalyzed cyanation and amidoximation

A novel "one-pot" reaction was developed for the synthesis of aryl or heteroaryl-substituted amidoxime compounds containing various functional groups. Fluorescence titration experiments coupled with theoretical analysis revealed that the steric hindrance and electronic effects of substituents influence the binding ability of the amidoxime compounds to uranyl ions. This journal is

PYRROLOTRIAZINE KINASE INHIBITORS

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

IMIDAZOPYRIDAZINE KINASE INHIBITORS USEFUL TO TREATING A DISEASE OR DISORDER MEDIATED BY AAK1, SUCH AS ALZHEIMER'S DISEASE, BIPOLAR DISORDER, PAIN, SCHIZOPHRENIA

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

COMPOUNDS AND METHODS for the inhibition of HDAC

Disclosed are compounds having the formula: wherein X1, X2, X3, R1, R2, R3, R4, Y, A, Z, L and n are as defined herein, and methods of making and using the same.

Design, synthesis and biological activity evaluation of 2,5-diphenyl-1,3,4-oxadiazole derivatives as novel inhibitors of fructose-1,6-bisphosphatase

Fructose-1,6-bisphosphatase (FBPase), an important gluconeogenic enzyme, catalyzes the hydrolysis of fructose 1,6-bisphosphate to fructose 6-phosphate. The effort to discover new FBPase inhibitors was carried out by high-throughput screening (HTS) of a library of 56,000 lead-like compounds, and a 2,5-diphenyl-1,3,4-oxadiazole (3a, IC50 = 15.45 μM) which bearing no phosphate group was identified as a potential FBPase inhibitor for the first time. Structure-activity-relationship (SAR) research of a series of analogues obtained by modifying the substituent groups and replacing the 1,3,4-oxadiazole with several other heterocycles disclosed the key structure and substituent groups related to the binding with FBPase.